[{"orgOrder":0,"company":"Futura Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MED3000","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Futura Medical \/ Undisclosed"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MED3000","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Futura Medical \/ Undisclosed"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MED3000","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Futura Medical \/ Undisclosed"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Futura Medical \/ Undisclosed"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Richmond Pharmacology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tetracaine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Futura Medical \/ Richmond Pharmacology","highestDevelopmentStatusID":"6","companyTruncated":"Futura Medical \/ Richmond Pharmacology"}]

Find Clinical Drug Pipeline Developments & Deals by Futura Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Eroxon (MED3000) is a topical gel formulation FDA approved in the US, CE marked in Europe and UKCA marked in the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

                          Product Name : Eroxon

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 12, 2023

                          Lead Product(s) : MED3000

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : In the USA all clinically proven oral ED therapies are prescription-only and therefore FM71/MED3000 has the potential to be a significant innovation with its key differentiator of a rapid speed of onset and by creating a major new OTC category for ED tre...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 31, 2022

                          Lead Product(s) : Tadalafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : MED3000 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Erectile Dysfunction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 02, 2021

                          Lead Product(s) : MED3000

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Futura Medical has received official minutes from the US Food and Drug Administration (FDA) for MED3000, the Company’s breakthrough fast acting clinically proven treatment for erectile dysfunction.

                          Product Name : Eroxon

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 22, 2021

                          Lead Product(s) : MED3000

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Tetracaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 30, 2020

                          Lead Product(s) : Tetracaine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Richmond Pharmacology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : MED2005 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Erectile Dysfunction.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 05, 2019

                          Lead Product(s) : MED2005

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : MED2005 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Erectile Dysfunction.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 23, 2019

                          Lead Product(s) : MED2005

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Ibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 28, 2016

                          Lead Product(s) : Ibuprofen

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Parexel

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Glyceryl Trinitrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Erectile Dysfunction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 13, 2015

                          Lead Product(s) : Nitroglycerin

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Richmond Pharmacology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank